Cancer drug prices slashed - (Business Line via NewsPoints Desk)

  • The National Pharmaceutical Pricing Authority (NPPA) has cut the prices of nine non-scheduled anti-cancer drugs by 30 percent to 60 percent, as reported Business Line Thursday.

  • The drugs targeted for the price cuts include erlotinab, pemetrexed, epirubician, leuprolide and everolimus.

  • The news comes after the NPPA slashed the prices of 380 drugs.

  • "The cost of a drug is escalated by almost up to eight times of the production cost in the supply chain with the middleman pocketing more than the manufacturer," explained Apollo Cancer Institute director Vijay Ananda Reddy, adding "in fact, the price reduction should be applied to all drugs across different brands."

  • "The reduction of prices as announced by the NPPA only sees margin rationalisation at individual drug level," a drug industry executive remarked, continuing "however, it overlooks the general cost of research and development in the long run."

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.

Reference Articles